Israel

Nir Kalkstein: My Algorithms Can Make Cash Or Detect Cancer

Having built one of the world's most successful algorithmic trading companies, Israeli entrepreneur Kalkstein now is putting his mathematical wizardry to saving lives.

Nir Kalkstein: My Algorithms Can Make Cash Or Detect Cancer
Shay Aspril

The following is a summary of a Calcalist cover story last month

TEL AVIV — Nir Kalkstein, one of Israel's most successful high-tech entrepreneurs, prefers to fly below the radar. He quietly made millions as the founder 14 years ago of Final, among the world's most successful algorithmic trading companies.

But by 2009 the super low-profile, bright mind behind this money machine came to the conclusion that he had achieved the scientific challenge he had set for himself. Moreover, he began to realize that Final was not generating value for the wider public, but was mainly using a technological advantage to fill up the pockets of its 30 shareholders.

This was the cue that led to Medial, Kalkstein's new venture. This time he is determined to rattle the medical world. Now employing 27 people, and financed personally by Kalkstein with millions of dollars every year, Medial had launched with the goal of developing an algorithmic system for early diagnosis of colorectal cancer.

"We are not the typical commercial company," Ofer Arieli, Kalkstein's business partner, told Calcalist. "We have a shareholder who committed to fund the company for the next years. So, if we are to choose between making a lot of money and saving few people on one hand, and earning little but saving many people on the other hand, we opt for the latter."

[rebelmouse-image 27089360 alt="""" original_size="458x300" expand=1]

Final and Medial founder Nir Kalkstein — Photo: Amit Sur/Calcalist

Kalkstein has told his team that even if Medial generates profit, he will reinvest it all in the company. "He doesn't need the money from Medial," notes Arieli. "He has enough."

Hong Kong cash

According to the World Health Organization, every year around 15 million people are diagnosed with cancer, and 7 to 8 million die of the disease.

Just like with Final, Medial's inception required obtaining a huge database that would allow the company's analysis of historical records. Negotiations with Israel's Maccabi Healthcare Services ended with a barter: blood test data in exchange for free diagnosis services. These were then matched with data received from the National Cancer Registry in the Israeli Health Ministry, and the algorithmic models produced are subsequently used for generating an assessment of a patient's likelihood of getting cancer. Similar algorithms will be used for diagnosing esophageal and stomach cancers, and another will try to identify lung cancer.

Medial has also expanded into five additional fields: alerts for deterioration in E.R. patients, identification of possible complications after cardiac catheterization, early detection of epilepsy attacks, early detection of heart failure, and quantifying the personal risk due to a patient's general check-up.

Two years ago Hong Kong business magnate Li Ka-shing agreed to invest in Medial, buying 28% of the share of the daughter company Medial Cancer Screening for $20 million.

And now Medial awaits its next milestone: for its algorithmic system to be approved by the U.S. Food and Drug Administration.

"I would have preferred you didn't publish this story now, but rather wait a year or two," Kalkstein tells Calcalist. "When you then come back we would tell you, not only about the models, but also about the people we saved. I hope it happens."

You've reached your monthly limit of free articles.
To read the full article, please subscribe.
Get unlimited access. Support Worldcrunch's unique mission:
  • Exclusive coverage from the world's top sources, in English for the first time.
  • Stories from the best international journalists.
  • Insights from the widest range of perspectives, languages and countries
Already a subscriber? Log in
Keep up with the world. Break out of the bubble.
Sign up to our expressly international daily newsletter!
Society

The Barber Of Amsterdam? Dutch Culture Sector's Hair-Razing COVID Protest

Theaters, museums and cinemas welcomed "essential services" on their stage floors to make a point about the industry's struggles during the latest COVID lockdown.

Theater Hairdresser a peaceful protest against Netherlands' continued nationwide lockdown in the arts sector

It’s an unusual sight even in these unusual times: in the Royal Concertgebouw, Amsterdam's prestigious concert hall, a man sits on stage getting his hair cut. Behind him, an orchestra plays Charles Ives' Symphony no. 2. In front of him, dozens of people are watching — both the orchestra, and to see when it's their turn for the next haircut.

Keep reading... Show less
Keep up with the world. Break out of the bubble.
Sign up to our expressly international daily newsletter!
You've reached your monthly limit of free articles.
To read the full article, please subscribe.
Get unlimited access. Support Worldcrunch's unique mission:
  • Exclusive coverage from the world's top sources, in English for the first time.
  • Stories from the best international journalists.
  • Insights from the widest range of perspectives, languages and countries
Already a subscriber? Log in
THE LATEST
FOCUS
TRENDING TOPICS
MOST READ